In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Pharma’s Big Problems: Insights From Novo Holdings CEO

The State Of Health Care According To Kasim Kutay

Executive Summary

Novo Holdings CEO Kasim Kutay discusses today’s financing challenges and tomorrows big pharma pipeline problems in an exclusive interview. Despite turbulent times, he is positive about the future of health care.

You may also be interested in...



Novo Splashes Out Again To Solve Semaglutide Supply Problem

Novo Nordisk is buying three manufacturing facilities for $11bn from Catalent, which has just been acquired by the former's main shareholder Novo Holdings, in its latest bid to meet surging demand for its semaglutide-based diabetes and obesity drugs.

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

AstraZeneca’s Soriot: UK’s Pharma Policies Have Already Hit Investment

Pascal Soriot claims the UK is undermining its life sciences sector, and the government needs to support market access and clinical trials in the country or face losing out to competing nations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel